CAJ | 학술논문

痛风是一种常见的风湿性疾病，目前，急性痛风常用非甾体抗炎药、秋水仙碱，但它们对伴有并发症的痛风患者无效；而在痛风发作的其他时期则可使用降尿酸药物。近年来黄嘌呤氧化酶（XOD）抑制剂和嘌呤核苷磷酸化酶（PNP）抑制剂等可抑制尿酸合成的药物成为这个领域的研究热点。本文主要介绍了白细胞介素1抑制剂（IL-1β抑制剂）、lesinurad、XOD 抑制剂、PNP 抑制剂的作用机制，临床效果和不良反应。
통풍시일충상견적풍습성질병，목전，급성통풍상용비치체항염약、추수선감，단타문대반유병발증적통풍환자무효；이재통풍발작적기타시기칙가사용강뇨산약물。근년래황표령양화매（XOD）억제제화표령핵감린산화매（PNP）억제제등가억제뇨산합성적약물성위저개영역적연구열점。본문주요개소료백세포개소1억제제（IL-1β억제제）、lesinurad、XOD 억제제、PNP 억제제적작용궤제，림상효과화불량반응。
Gout is a common rheumatologic disorder and non-steroidal anti-inflammatory drugs and colchicine have been currently used for its treatment during its acute attack period. Although these drugs are generally effective, it may be contraindicated especially in patients with concomitant comorbidities while urate-lowering drugs can be used during other periods. In recent years, both xanthine oxidase (XOD) and purine nucleoside phosphorylase (PNP) inhibitors have become a hot topic of research in this field. This paper describes the mechanism of action of the interleukin-1 inhibitor (IL-1β inhibitors), lesinurad, XOD and PNP inhibitors, their clinical effects and adverse reactions.